Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Sehgal, Alison R.; Hoda, Daanish; Riedell, Peter A.; Ghosh, Nilanjan; Hamadani, Mehdi; Hildebrandt, Gerhard; Godwin, John; Reagan, Patrick M.; Wagner‐Johnston, Nina D.; Essell, James; Nath, Rajneesh; Solomon, Scott R.; Champion, Rebecca; Licitra, Edward J.; Fanning, Suzanne R.; Gupta, Neel K.; Dubowy, Ronald L.; D’Andrea, Aleco; Wang, Lei; Ogasawara, Kunio; Thorpe, Jerill; Gordon, Leo I.

doi:10.1016/s1470-2045(22)00339-4

Cited by 127 publications

(107 citation statements)

References 30 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…Recently presented PILOT study results for patients with relapse LBCL who are deemed ineligible for transplant (meeting one of the following criteria: age ⩾70 years, Eastern Cooperative Oncology Group performance status ⩾2, diffusing capacity for carbon monoxide ⩽60%, left ventricular ejection fraction <50%, creatinine clearance < 60 mL/min, or alanine transaminase/aspartate transaminase > 2× upper limit of normal) and received liso-cel as a second line showed promising results with an ORR of 80% and CR of 54%, with a median duration of response of 12.1 months, and PFS of 9 months. 27 Because of the results of the PILOT study, liso-cel is also FDA approved for patients that relapse after first-line chemoimmunotherapy and are not eligible for auto-HCT due to comorbidities or age.…”

Section: Discussionmentioning

confidence: 99%

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

Albanyan

Chávez

Muñoz

2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

Albanyan

Chávez

Muñoz

2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…With a median follow-up of 12.3 months, 54% of patients achieved a CR, the median PFS was 9 months, and median OS was not reached. 65 Liso-cel should be considered for patients not candidates for ASCT.…”

Section: Therapeutic Approachesmentioning

confidence: 99%

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

Nastoupil

Bartlett

2023

JCO

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases. Several recent advances have affected the treatment landscape, which had been mostly stagnant for the past few decades. We will review the practice-changing studies in frontline (POLARIX), early relapse (ZUMA-7 and TRANSFORM), and multiple recurrent (ZUMA-1, JULIET, TRANSCEND, L-MIND, and LOTIS-2) stages and discuss how the treatment landscape may evolve with the emergence of bispecific antibodies.

show abstract

“…61 patients at a median age of 74 with r/r LBCL who experienced less than a CR to first‐line chemoimmunotherapy received a single infusion of liso‐cel 22 . Ineligibility for transplant was based on age 70 or older, ECOG performance status of 2, and/or end organ dysfunction 22 . At a median follow‐up time of 12 months, the ORR was 80%, including 54% with CR 22 .…”

Section: Car T‐cell Therapy In the Second‐line For Lbclmentioning

confidence: 99%

CAR T‐cell therapy in large B cell lymphoma

Boardman

Salles

2023

Hematological Oncology

View full text Add to dashboard Cite

CD19-targeted chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19-CAR T-cell products received FDA and EMA approval designations in lymphoma in the third-line setting, paving the way for follow-up studies in the second-line. Meanwhile, investigations into the applications of CAR T-cell therapy have further broadened to treating high-risk patients even prior to completion of first-line conventional chemo-immunotherapy. Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19-CAR T-cells in primary and secondary CNS lymphoma. Here we provide a detailed overview on clinical data supporting the use of CAR T-cells in patients with LBCL.

show abstract

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Cited by 127 publications

References 30 publications

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

CAR T‐cell therapy in large B cell lymphoma

Contact Info

Product

Resources

About